KAZIA: US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB

  Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer.

https://finance.yahoo.com/news/us-fda-awards-orphan-drug-120000433.html